CLAIMS

**1.** Use of a CCR2 chemokine receptor antagonist and a PD-1 and/or PD-L1 inhibitor in the preparation of a medicament for treating colorectal cancer in mammal, wherein the CCR2 chemokine receptor antagonist is to be administered in combination, concomitantly or sequentially with the PD-1 and/or PD-L1 inhibitor, and wherein the CCR2 chemokine receptor antagonist has the formula selected from the group consisting of



(Compound 1)



(Compound 2)



(Compound 3)

or a pharmaceutically acceptable salt thereof.

**2**. The use of claim **1**, wherein said CCR2 inhibitor has the formula



(Compound 1)

or a pharmaceutically acceptable salt thereof.

**3**. The use of claim **1**, wherein said CCR2 inhibitor has the formula



(Compound 2)

or a pharmaceutically acceptable salt thereof.

**4**. The use of claim **1**, wherein said CCR2 inhibitor has the formula



(Compound 3)

or a pharmaceutically acceptable salt thereof.

**5**. The use of any one of claims **1** to **4**, wherein said PD-1 and/or PD-L1 inhibitor is a PD-1 inhibitor.

**6**. The use of claim **5**, wherein the PD-1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, IBI-308, mDX-400, BGB-108, MEDI-0680, SHR-1210, PF-06801591, PDR-001, GB-226, and STI-1110.

**7**. The use of claim **5**, wherein the PD-1 inhibitor is selected from the group consisting of Nivolumab, Pembrolizumab, and Pidilizumab.

**8**. The use of any one of claims **1** to **4**, wherein said PD-1 and/or PD-L1 inhibitor is a PD-L1 inhibitor.

**9**. The use of claim **8**, wherein the PD-L1 inhibitor is selected from the group consisting of durvalumab, atezolizumab, avelumab, BMS-936559, ALN-PDL, TSR-042, KD-033, CA-170, CA-327, STI-1014, and KY-1003.

**10**. The use of any one of claims **1** to **9**, wherein the CCR2 chemokine receptor antagonist and the PD-1 inhibitor and/or the PD-L1 inhibitor are to be administered concomitantly.

**11**. The use of claim **10**, wherein the CCR2 chemokine receptor antagonist, and the PD-1 inhibitor and/or the PD-L1 inhibitor are to be administered in a combination formulation.

**12**. The use of any one of claims **1** to **9**, wherein the CCR2 chemokine receptor antagonist, and the PD-1 inhibitor and/or the PD-L1 inhibitor are to be administered sequentially.

**13**. The use of claim **12**, wherein the CCR2 chemokine receptor antagonist is to be administered prior to administration of the PD-1 inhibitor and/or the PD-L1 inhibitor.

**14**. The use of claim **12**, wherein the CCR2 chemokine receptor antagonist is to be administered after the administration of the PD-1 inhibitor and/or the PD-L1 inhibitor.

**15**. The use of any one of claims **1** to **14**, wherein the CCR2 chemokine receptor antagonist is to be administered orally and the PD-1 inhibitor and/or the PD-L1 inhibitor is to be administered intravenously.

**16**. The use of any one of claims **1** to **15**, wherein the mammal is a human subject.

**17**. A composition for use in treating a subject having colorectal cancer, comprising a therapeutically effective amount of a CCR2 chemokine receptor antagonist, a therapeutically effective amount of a PD-1 inhibitor and/or a PD-L1 inhibitor, and a pharmaceutically acceptable carrier or excipient, wherein the CCR2 chemokine receptor antagonist has the formula selected from the group consisting of




(Compound 1)



(Compound 2)



(Compound 3)

or a pharmaceutically acceptable salt thereof.

**18** The composition of claim **17**, wherein the CCR2 chemokine receptor is selected from any one of claims **1-4**.

**19**. The composition of claim **17** or claim **18**, wherein the PD-1 inhibitor and/or the PD-L1 inhibitor is selected from any one of claims **5** to **9**.

**20**. A kit for use in treating a subject having colorectal cancer, said kit comprising a CCR2 chemokine receptor antagonist and a PD-1 inhibitor and/or a PD-L1 inhibitor, with instruction for effective administration, wherein the CCR2 chemokine receptor antagonist has the formula selected from the group consisting of



(Compound 1)



(Compound 2)



(Compound 3)

or a pharmaceutically acceptable salt thereof.

**21**. Use of a CCR2 chemokine receptor antagonist and a PD-1 inhibitor and/or a PD-L1 Inhibitor in the manufacture of a kit for treating a subject having a colorectal cancer, wherein the CCR2 chemokine receptor antagonist has the formula selected from the group consisting of



(Compound 1)



(Compound 2)



(Compound 3)

or a pharmaceutically acceptable salt thereof.

**22**. Use of a CCR2 chemokine receptor antagonist and a PD-1 inhibitor and/or a PD-L1 Inhibitor in the manufacture of a medicament, included in a kit, for treating a subject having colorectal cancer, wherein the CCR2 chemokine receptor antagonist has the formula selected from the group consisting of



(Compound 1)



(Compound 2)



(Compound 3)

or a pharmaceutically acceptable salt thereof.

**23**. The kit of claim **20** or the use of claim **21** or claim **22**, wherein the CCR2 chemokine receptor is selected from any one of claims **1-4**.

**24**. The kit of claim **20** or claim **23** or the use of any of claims **21-23**, wherein the PD-1 inhibitor and/or the PD-L1 inhibitor is selected from any one of claims **5** to **9**.

**25**. The kit of any one of claims **20** and **23** or **24** or the use of any one of claims **21-24**, wherein the CCR2 chemokine receptor antagonist and the PD-1 inhibitor and/or the PD-L1 inhibitor are formulated for concomitant administration.

**26**. The kit of any one of claims **20** and any one of claims 23 to 25 or the use of any one of claims **21** to **25**, wherein the CCR2 chemokine receptor antagonist and the PD-1 inhibitor and/or the PD-L1 inhibitor are formulated for sequential administration.

**27**. A kit for use in treating a subject having a solid tumor cancer, said kit comprising a CCR2 chemokine receptor antagonist and a PD-1 inhibitor and/or a PD-L1 inhibitor as a combined preparation for simultaneous, concomitant; separate or sequential use in the subject, wherein the CCR2 chemokine receptor antagonist has the formula selected from the group consisting of




(Compound 1)




(Compound 2)




(Compound 3)

or a pharmaceutically acceptable salt thereof